26 jul: Roche Gets FDA Clearance For Vitamin D Laboratory Test
26 jul: PKN Orlen Swings to Net Loss of PLN5.2 Million
26-07-2012 07:54:00

Sanofi Second-Quarter Net Profit up 16% Boosted by Tax Effect

Relateret indhold
Relateret debat
11 nov - 
It is very respective and fascinating topic to grab the..
11 nov - 
Sanofi and Regeneron Announce Positive Results from Pha..
29 okt - 
Uroen kan vel kun komme Novo til fordel. http://www.fin..

By Noemie Bisserbe

PARIS--France's top drug maker Sanofi SA (SNY, SAN.FR) said Thursday it expected its earnings to fall this year, dented by the loss of patents on some of its blockbuster drugs, even as it posted a firm increase in second-quarter net profit, boosted by a tax effect.

The Paris-based pharmaceutical major said net profit attributable to shareholders rose 16% to 1.17 billion euros (US$1.4 billion) in the quarter ended June 30, from EUR1.01 billion a year earlier.

Business net income--the term it uses for adjusted income excluding items such as impacts associated with acquisitions and divestments--was, however, down 9.6% to EUR1.94 billion, hit by the loss of its patents on top-selling drugs--blood thinner Plavix and Avapro, a drug used to treat high blood pressure.

Analysts had forecast a second-quarter business net profit of EUR1.88 billion.

Sanofi's woes underscore drug makers' growing difficulty in keeping their heads above water as they swim from one blockbuster drug to another. On Wednesday, GlaxoSmithKline PLC (GSK), Bristol-Myers Squibb Co. (BMY) and Eli Lilly & Co. (LLY) reported sharp drops in second-quarter net profit, hit by a wave of patent expirations for top-selling drugs.

Sanofi maintained its full-year guidance for a 12% to 15% decline in business earnings per share in 2012, assuming no major changes in exchange rates.

Analysts, however, expect Sanofi's earnings to rebound from 2013, as the group strives to rely less on innovative drug sales.

Sanofi, which is struggling with patent expirations, has been extending its pharmaceutical business to growth areas such as emerging markets, vaccines, diabetes solutions, consumer health care, innovative products and animal health, in a bid to become less dependent on patented medicines.

Net sales rose 6.2% to EUR8.87 billion, with revenue at the flagship pharmaceutical division increasing 5.1% to EUR7.5 billion.

Write to Noemie Bisserbe at noemie.bisserbe@dowjones.com

Order free Annual Report for Sanofi

Visit http://djnweurope.ar.wilink.com/?ticker=US80105N1054 or call +44 (0)208 391 6028

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 26, 2012 01:54 ET (05:54 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Lundbeck/SEB: Data for nyt skizofrenimiddel er solide

26-11-2014 16:07:10
Lundbeck har stillet fase 3-data for sit nye skizofreni- og depressionsmiddel, Brexpiprazol, i udsigt under en medicinalkonference den 7-11. december, og der er..

Genmab/Jyske: Øger kursmål på potentiale i Daratumumab

26-11-2014 14:13:48
Jyske Bank ser et stort kommercielt potentiale i Genmab-stoffet Daratumumab, som for tiden testes i en stribe forsøg, der skal afdække, om midlet kan hjælpe mod..

Vestas vinder ordre på 49 MW i Den Dominikanske Republik - NY

26-11-2014 10:33:06
Vestas har sikret sig en ordre i Den Dominikanske Republik på 15 møller med en samlet kapacitet på 49,5 megawatt, oplyser selskabet på sin hjemmeside.Der er tal..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas vinder ordre på 49 MW i Den Dominikanske Republik - NY
2
SAS-aktien er steget 23 pct. på en uge
3
Genmab/Jyske: Øger kursmål på potentiale i Daratumumab
4
Aktier/tendens: Lettere positiv åbning i vente
5
Comendo indgår aftale om salg for 85 mio. kr. - NY

Relaterede aktiekurser

Sanofi 76,43 0,3% Stigning i aktiekurs
Sanofi 48,03 0,8% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen
Sælg

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
26. november 2014 18:20:57
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20141125.1 - EUROWEB5 - 2014-11-26 18:20:57 - 2014-11-26 18:20:57 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x